Enovis (NYSE:ENOV) Director Sharon Wienbar Buys 874 Shares of Company Stock

November 13, 2026 by InsiderTrades.com

Key Points

Enovis Director Sharon Wienbar bought 874 shares at an average price of $28.43, spending about $24,848 and increasing her company stake by 2% to 44,651 shares.
Enovis reported quarterly EPS of $0.88, beating the $0.77 consensus estimate; revenue of $558.73 million also slightly exceeded expectations and rose 1.8% year over year.
Analysts have a consensus Moderate Buy rating on the stock, with an average price target of $38.62; shares were reported down 3.2%.

Enovis Corporation (NYSE:ENOV - Get Free Report) Director Sharon Wienbar bought 874 shares of the stock in a transaction that occurred on Tuesday, November 10th. The shares were purchased at an average price of $28.43 per share, for a total transaction of $24,847.82. Following the purchase, the director owned 44,651 shares in the company, valued at $1,269,427.93. This represents a 2.00% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Enovis Trading Down 3.2%

Shares of ENOV stock opened at $27.63 on Friday. Enovis Corporation has a 52-week low of $16.70 and a 52-week high of $31.81. The company has a debt-to-equity ratio of 0.82, a quick ratio of 1.08 and a current ratio of 2.15. The firm has a market capitalization of $1.59 billion, a PE ratio of -3.00 and a beta of 1.31. The stock has a fifty day simple moving average of $20.36 and a two-hundred day simple moving average of $23.19.

Enovis (NYSE:ENOV - Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The company reported $0.88 EPS for the quarter, beating analysts' consensus estimates of $0.77 by $0.11. Enovis had a positive return on equity of 13.23% and a negative net margin of 22.86%. The business had revenue of $558.73 million for the quarter, compared to analysts' expectations of $557.12 million. During the same period last year, the firm earned $0.75 earnings per share. The business's quarterly revenue was up 1.8% on a year-over-year basis. On average, analysts predict that Enovis Corporation will post 3.15 EPS for the current fiscal year.

Recent Enovis Headlines

Here are a few of the latest headlines about ENOV:

Positive Sentiment: Directors Angela S. Lalor and Sharon L. Wienbar reported purchases on November 10 and 11, totaling 3,531 shares worth about $100,000. The buying may bolster investor confidence, although the transactions are relatively modest and do not guarantee future performance. Lalor SEC filing Wienbar SEC filing
Neutral Sentiment: Enovis said management will present at the Jefferies Global Healthcare Conference in London on November 17. The announcement provides an opportunity for investors to hear from management but disclosed no new financial guidance or business developments. Conference announcement

Analyst Ratings Changes

ENOV has been the topic of a number of research analyst reports. Citigroup reissued a "market outperform" rating on shares of Enovis in a report on Wednesday, September 2nd. BTIG Research increased their price objective on shares of Enovis from $36.00 to $42.00 and gave the company a "buy" rating in a report on Thursday, November 5th. Needham & Company LLC increased their price objective on shares of Enovis from $34.00 to $38.00 and gave the company a "buy" rating in a report on Thursday, November 5th. Weiss Ratings upgraded shares of Enovis from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Monday, November 2nd. Finally, Canaccord Genuity Group reduced their price objective on shares of Enovis from $45.00 to $42.00 and set a "buy" rating on the stock in a research report on Friday, November 6th. Ten analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $38.62.

Read Our Latest Stock Analysis on Enovis

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in ENOV. Paradigm Capital Management Inc. NY boosted its holdings in shares of Enovis by 70.2% during the 1st quarter. Paradigm Capital Management Inc. NY now owns 1,776,715 shares of the company's stock valued at $40,420,000 after purchasing an additional 732,917 shares during the last quarter. Private Management Group Inc. increased its holdings in shares of Enovis by 31.3% in the third quarter. Private Management Group Inc. now owns 1,792,429 shares of the company's stock worth $32,748,000 after purchasing an additional 427,347 shares during the last quarter. Allspring Global Investments Holdings LLC increased its holdings in shares of Enovis by 38.0% in the first quarter. Allspring Global Investments Holdings LLC now owns 1,045,360 shares of the company's stock worth $24,430,000 after purchasing an additional 287,687 shares during the last quarter. Front Street Capital Management Inc. increased its holdings in shares of Enovis by 106.1% in the first quarter. Front Street Capital Management Inc. now owns 746,056 shares of the company's stock worth $16,973,000 after purchasing an additional 384,124 shares during the last quarter. Finally, Quantinno Capital Management LP lifted its position in shares of Enovis by 130.8% in the first quarter. Quantinno Capital Management LP now owns 604,500 shares of the company's stock worth $13,752,000 after buying an additional 342,556 shares in the last quarter. Institutional investors own 98.45% of the company's stock.

About Enovis

(Get Free Report)

Enovis is a medical technology company that develops products and solutions for orthopedic care, surgery, recovery and rehabilitation. Its offerings include joint replacement implants, foot and ankle products, surgical instruments, orthopedic braces and supports, and rehabilitation equipment. The company serves healthcare providers and patients in markets around the world. Its products are designed to support treatment across different stages of musculoskeletal care, from surgical intervention to recovery and mobility.